HK1251567A1 - 用於激酶抑制的杂芳基化合物 - Google Patents

用於激酶抑制的杂芳基化合物 Download PDF

Info

Publication number
HK1251567A1
HK1251567A1 HK18111064.8A HK18111064A HK1251567A1 HK 1251567 A1 HK1251567 A1 HK 1251567A1 HK 18111064 A HK18111064 A HK 18111064A HK 1251567 A1 HK1251567 A1 HK 1251567A1
Authority
HK
Hong Kong
Prior art keywords
kinase inhibition
heteroaryl compounds
compounds
mutant
kinase activity
Prior art date
Application number
HK18111064.8A
Other languages
English (en)
Chinese (zh)
Inventor
Tianjun ZHOU
Willmen W. YOUNGSAYE
William C. Shakespeare
Alexey V. Ishchenko
Wei-Sheng Huang
David C. Dalgarno
Original Assignee
Ariad Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharmaceuticals, Inc. filed Critical Ariad Pharmaceuticals, Inc.
Publication of HK1251567A1 publication Critical patent/HK1251567A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
HK18111064.8A 2015-05-13 2016-05-12 用於激酶抑制的杂芳基化合物 HK1251567A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562160989P 2015-05-13 2015-05-13
US201562160989P 2015-05-13

Publications (1)

Publication Number Publication Date
HK1251567A1 true HK1251567A1 (zh) 2019-02-01

Family

ID=57249337

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111064.8A HK1251567A1 (zh) 2015-05-13 2016-05-12 用於激酶抑制的杂芳基化合物

Country Status (5)

Country Link
US (1) US20210323976A1 (enExample)
EP (1) EP3294712A4 (enExample)
JP (1) JP6863901B2 (enExample)
HK (1) HK1251567A1 (enExample)
WO (1) WO2016183278A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
JP2019501222A (ja) 2016-01-07 2019-01-17 シーエス ファーマテック リミテッド Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬
CN108299419B (zh) * 2017-01-11 2022-04-26 南京圣和药业股份有限公司 一种新型egfr激酶抑制剂的几种新晶型及其制备方法
CN109705118B (zh) * 2017-10-25 2021-12-28 南京圣和药业股份有限公司 三环类egfr激酶抑制剂的制备方法
CN109705117A (zh) * 2017-10-25 2019-05-03 南京圣和药业股份有限公司 三环类化合物、其制备方法及用途
CN108191861B (zh) * 2018-03-01 2020-10-02 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺
CA3143919A1 (en) * 2019-06-20 2020-12-24 Oncobix Co., Ltd. Pyrimidine derivative inhibiting growth of cancer cell and medicinal use thereof
EP4100412A1 (en) * 2020-02-03 2022-12-14 Boehringer Ingelheim International GmbH [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
JP7626773B2 (ja) 2020-02-03 2025-02-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
US11608343B2 (en) * 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
CN112409192A (zh) * 2020-11-26 2021-02-26 启东东岳药业有限公司 一种4-氟-2-甲氧基苯胺的纯化方法
BR112023021111A2 (pt) 2021-04-13 2023-12-19 Nuvalent Inc Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960572B2 (en) * 2001-06-21 2005-11-01 Ariad Pharmaceuticals, Inc. Indolinones and uses thereof
TWI475996B (zh) * 2007-10-19 2015-03-11 Celgene Avilomics Res Inc 雜芳基化合物及其用途
WO2009143389A1 (en) * 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) * 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8450335B2 (en) * 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
ME02887B (me) * 2011-07-27 2018-04-20 Astrazeneca Ab 2-(2,4,5-supstituisani-anilino) pirimidinski derivati kao egfr modulatori korisni za tretman raka
EP3057954A2 (en) * 2013-10-18 2016-08-24 Syros Pharmaceuticals, Inc. Heteromaromatic compounds useful for the treatment of proliferative diseases
JP6468611B2 (ja) * 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
AP2017009690A0 (en) * 2014-06-19 2017-01-31 Ariad Pharma Inc Heteroaryl compounds for kinase inhibition
CA2984586C (en) * 2015-04-29 2021-02-16 Guangdong Zhongsheng Pharmaceutical Co., Ltd. Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor

Also Published As

Publication number Publication date
EP3294712A4 (en) 2018-11-07
WO2016183278A1 (en) 2016-11-17
JP6863901B2 (ja) 2021-04-28
US20210323976A1 (en) 2021-10-21
JP2018515514A (ja) 2018-06-14
EP3294712A1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
MY186839A (en) Heteroaryl compounds for kinase inhibition
HK1251567A1 (zh) 用於激酶抑制的杂芳基化合物
ZA201801724B (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
EP3481402A4 (en) CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE
EP3484504A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE
EP3340981A4 (en) ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISEASES
LT3604294T (lt) Junginiai ir kompozicijos, skirti egfr mutantinės kinazės veiklos moduliavimui
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12016500582B1 (en) Heterocyclic compounds and uses thereof
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
EP3394047A4 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
AU2017248276A1 (en) Methods of treating ocular conditions
EP4413974A3 (en) Methods of treating ocular conditions
WO2014110198A3 (en) Therapeutic indications of kinase inhibitors
HK1249756A1 (zh) 用於治疗疾病的稠合双环化合物
EP3820477A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
EP3831365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ATOPIC DISEASES
WO2015145388A3 (en) Methods of treating colorectal cancers harboring upstream wnt pathway mutations
NZ763986A (en) Heteroaryl compounds for kinase inhibition
HK40122446A (zh) 包含4-苯并吡喃酮衍生物的用於预防或治疗肿瘤坏死因子相关疾病的组合物
TH1601007484A (th) สารประกอบเฮเทอโรแอริลสำหรับการยับยั้งไคเนส
MX2019014773A (es) Inhibidores de ccl2.
HK1247584A1 (zh) 結晶c21h22c12n4o2丙二酸酯